Stryker Corporation 10-Q Summary: Q1 2008
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Stryker Corporation, a leading medical technology company, for the period ended March 31, 2008. The company operates in two primary segments: Orthopaedic Implants and MedSurg Equipment. Stryker is a large accelerated filer incorporated in Michigan. As of March 31, 2008, there were 411,793,508 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Net Sales | $1,634.4 million | $1,425.5 million |
| Gross Profit | $1,133.9 million (69.4% margin) | $986.1 million (69.2% margin) |
| Operating Income | $383.7 million | $322.2 million |
| Net Earnings (Continuing Ops) | $290.5 million | $241.8 million |
| Diluted EPS (Continuing Ops) | $0.70 | $0.58 |
| Cash from Operations | $190.8 million | $152.7 million |
| Cash & Equivalents | $423.5 million | $290.5 million (Dec 31, 2007) |
| Marketable Securities | $1,939.3 million | $2,120.3 million (Dec 31, 2007) |
| Debt (Current Maturities) | $17.7 million | $16.8 million (Dec 31, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15% year-over-year. On a constant currency basis, sales grew 10%, driven by volume and mix. Foreign exchange rates provided a favorable 4% impact.
- Segment Performance:
- Orthopaedic Implants: Sales rose 12% (7% constant currency). Growth was led by Trauma (+24%), Spine (+22%), and Knee (+14%) systems. Hip sales declined 1% on a constant currency basis due to the Trident cup recall.
- MedSurg Equipment: Sales rose 18% (15% constant currency), driven by surgical equipment, endoscopic systems, and patient handling products.
- Profitability: Operating income increased 19%. Gross margin improved slightly to 69.4% due to increased absorption from new products and inventory replenishment, partially offset by higher excess inventory costs.
- Working Capital: Working capital increased to $3,914.7 million. Days sales outstanding increased to 60 days, and days sales in inventory increased to 162 days, attributed to inventory buildup for product launches and currency effects.
Guidance, Outlook, and Risks
- 2008 Outlook: Management projects diluted net earnings per share of approximately $2.88 for 2008, a 22% increase over 2007. Constant currency net sales growth is projected at 11% to 13%.
- Auction-Rate Securities (ARS): The company holds $167.2 million (par) in ARS. Due to global credit market liquidity issues, auctions for these securities have failed since February 2008. The fair value is estimated at $159.5 million. The company has reclassified these as non-current assets and intends to hold them to maturity, asserting no impact on liquidity.
- Regulatory & Legal:
- SEC/DOJ: The company is cooperating with an informal SEC inquiry and a DOJ subpoena regarding potential Foreign Corrupt Practices Act violations.
- FDA: Received a warning letter in 2008 regarding quality systems at the OP-1 facility in Massachusetts, following two letters in 2007 for other facilities.
- Non-Prosecution Agreement: Subject to an 18-month federal monitor regarding consulting contracts with orthopedic surgeons.
- Acquisitions: Acquired Sightline Technologies (endoscopes) and PlasmaSol Corp (sterilization) in prior years; commercialization of these technologies is ongoing.
Investor Verification Checklist
- Verify the liquidity status and potential impairment risk of the $167.2 million ARS portfolio given the ongoing auction failures.
- Monitor the impact of the Trident hip cup recall on future Orthopaedic Implants revenue and warranty costs.
- Assess the financial impact of ongoing regulatory investigations (SEC, DOJ, FDA) and the costs associated with the federal monitor.
- Review the inventory buildup (162 days sales) to ensure it aligns with anticipated demand and does not lead to future write-downs.
- Confirm the timeline for commercialization of Sightline and PlasmaSol technologies to validate future growth projections.